Unknown

Dataset Information

0

Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.


ABSTRACT:

Introduction

Early prognostic factors for the clinical response in patients with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated.

Methods

Thirty-five patients with RA with an inadequate response to methotrexate were enrolled and administered IFX (3-9 mg/kg, every 4-8 weeks). Serum trough levels of IFX and levels of 9 cytokines were measured at baseline and at 3, 6 months, and 1 year. Associations between these parameters and clinical indicators were statistically analyzed.

Results

Serum trough levels of IFX and serum levels of interleukin (IL)-6 in the early phase of IFX treatment were investigated. Patients with low serum IL-6 achieved a higher clinical response as evaluated by the European League Against Rheumatism response criteria. Notably, the serum levels of IL-6 and IL-10 at baseline exhibited a significant positive correlation with disease activity at 1 year. Low serum levels of IL-6 and IL-10 at baseline were associated with low Disease Activity Score 28 erythrocyte sedimentation rate (DAS28-ESR). Cut-off values of IL-6 (5.45 pg/mL) and IL-10 and (1.68 pg/mL) enabled discrimination of DAS28-ESR remission from non-remission with high sensitivity and moderate specificity.

Conclusion

Following the initiation of IFX treatment, early disease activity and remission were associated with serum levels of IL-6. Serum levels of IL-6 and IL-10 at baseline predict the efficacy after 1 year of treatment with IFX. Patients with high serum levels of IL-6 and IL-10 at baseline before IFX treatment might require more intensive therapy to achieve higher rates of clinical remission at 1 year.

Funding

Eisai Co., Ltd.

SUBMITTER: Hayashi S 

PROVIDER: S-EPMC4999572 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate.

Hayashi Satoko S   Suzuki Katsuya K   Yoshimoto Keiko K   Takeshita Masaru M   Kurasawa Takahiko T   Yamaoka Kunihiro K   Takeuchi Tsutomu T  

Rheumatology and therapy 20151211 1


<h4>Introduction</h4>Early prognostic factors for the clinical response in patients with rheumatoid arthritis (RA) after 1 year of treatment with infliximab (IFX) as part of routine clinical practice were investigated.<h4>Methods</h4>Thirty-five patients with RA with an inadequate response to methotrexate were enrolled and administered IFX (3-9 mg/kg, every 4-8 weeks). Serum trough levels of IFX and levels of 9 cytokines were measured at baseline and at 3, 6 months, and 1 year. Associations betw  ...[more]

Similar Datasets

| S-EPMC2770104 | biostudies-literature
| S-EPMC4316868 | biostudies-literature
| S-EPMC5549282 | biostudies-other
| S-EPMC3701736 | biostudies-literature
| S-EPMC4964179 | biostudies-other
| S-EPMC10321123 | biostudies-literature
| S-EPMC7768454 | biostudies-literature
| S-EPMC5036216 | biostudies-other
| S-EPMC7589242 | biostudies-literature
| S-EPMC5129587 | biostudies-literature